MedTrace Logo

Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

NCT07248956 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2025-12-23

No results posted yet for this study

Summary

This is a multi-center, randomized controlled, prospective clinical study.

Conditions

  • Hypopharyngeal Carcinoma

Interventions

DRUG

Finolizumab

200mg every 3 weeks (q3w) for 2 cycles.

DRUG

Albumin-Bound Paclitaxel /nab-Paclitaxel

260mg/m², day 1, every 3 weeks (q3w) for 2 cycles.

DRUG

Cisplatin

25mg/m², days 1-3, every 3 weeks (q3w) for 2 cycles.

RADIATION

Definitive radiotherapy

Definitive radiotherapy (68-70Gy) with concurrent cisplatin-based chemotherapy (25mg/m², days 1-3, every 3 weeks)

PROCEDURE

Surgery with postoperative radiotherapy or chemoradiotherapy.

surgery with postoperative radiotherapy or chemoradiotherapy.

Sponsors & Collaborators

  • Eye & ENT Hospital of Fudan University

    lead OTHER

Principal Investigators

  • Ming Zhang, PhD · Eye & ENT Hospital, Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-22
Primary Completion
2027-11-30
Completion
2029-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07248956 on ClinicalTrials.gov